News Nexalin Technology, Inc.

Equities

NXL

US65345B2016

Market Closed - Nasdaq Other stock markets 02:00:01 30/05/2024 am IST			5-day change	1st Jan Change
0.6747 ^USD	-26.26%		-41.33%	+66.67%

10/05	Nexalin Technology, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI
25/04	Nexalin Technology Regains Compliance With Nasdaq Listing Requirement	MT

Summary

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Nexalin America Selected to Join the National Traumatic Brain Injury Registry Coalition to Propel TBI Awareness and Research Efforts	22/05	GL
Nexalin Technology, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	11/05	CI
Join Nexalin Technology’s Exclusive Live Investor Webinar and Q&A Session on May 23	09/05	GL
Nexalin Technology Regains Compliance With Nasdaq Listing Requirement	25/04	MT
Nexalin Technology Regains Compliance with Nasdaq Continued Listing Requirements	25/04	GL
Nexalin Technology : unveils positive results of clinical study for Gen-2 tACS device	18/04	PU
Nexalin Technology Files $5.6 Million Shelf Registration	16/04	MT
Nexalin Technology CEO Provides Letter to Shareholders	10/04	AQ
Nexalin Technology Accelerates Manufacturing of its HALO™ Clarity Following Successful Usability, Feasibility, and Electrical Testing	09/04	GL
Nexalin Technology Accelerates Manufacturing of Its HALO? Clarity Following Successful Usability, Feasibility, and Electrical Testing	09/04	CI
Nexalin Technology Awarded Key Patent Related to its Gen-3 HALO Clarity™, a Non-Invasive, Frequency-Based Deep-Brain Stimulation Device	04/04	GL
Nexalin Technology unveils positive results of clinical study for Gen-2 tACS device	04/04	AQ
Nexalin Technology Announces the Appointment of Government Affairs Veteran William A. Hudson, Jr. to Military & Government Advisory Board	02/04	GL
Nexalin Technology, Inc. Announces the Appointment of William A. Hudson, Jr. to Military & Government Advisory Board	02/04	CI
Top Midday Gainers	28/03	MT
Nexalin Technology Announces Positive Results of Clinical Study Validating its Gen-2 tACS Device for Reducing Pain Among Veterans with Mild Traumatic Brain Injury at University of California, San Diego	28/03	GL
Nexalin Technology, Inc. Announces Positive Results of Clinical Study Validating its Gen-2 TACS Device for Reducing Pain Among Veterans with Mild Traumatic Brain Injury at University of California, San Diego	28/03	CI
Nexalin Technology, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	28/03	CI
Nexalin Technology Commences Sales of Gen-2 Neurostimulation Device to New Mental Health Center in Oman Dedicated to Nexalin’s Technology	14/03	GL
Nexalin Technology, Inc. Commences Sales of Gen-2 Neurostimulation Device to New Mental Health Center in Oman	14/03	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

News Nexalin Technology, Inc.

Equities

NXL

US65345B2016

Summary

Filters